38 related articles for article (PubMed ID: 38536949)
1. A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune.
Jiang Z; Cai G; Liu H; Liu L; Huang R; Nie X; Gui R; Li J; Ma J; Cao K; Luo Y
J Nanobiotechnology; 2024 May; 22(1):296. PubMed ID: 38811964
[TBL] [Abstract][Full Text] [Related]
2. Homologous-targeting biomimetic nanoparticles co-loaded with melittin and a photosensitizer for the combination therapy of triple negative breast cancer.
Zhang T; Bai L; You R; Yang M; Chen Q; Cheng Y; Qian Z; Wang Y; Liu Y
J Mater Chem B; 2024 Jun; 12(22):5465-5478. PubMed ID: 38742364
[TBL] [Abstract][Full Text] [Related]
3. Biomimetic "nano-spears" for CAFs-targeting: splintered three "shields" with enhanced cisplatin anti-TNBC efficiency.
Wu Y; Chen R; Ni S; Hu K
J Control Release; 2024 Jun; 370():556-569. PubMed ID: 38697316
[TBL] [Abstract][Full Text] [Related]
4. Enhancing the Inhibition of Breast Cancer Growth Through Synergistic Modulation of the Tumor Microenvironment Using Combined Nano-Delivery Systems.
Wu J; Lu Q; Zhao J; Wu W; Wang Z; Yu G; Tian G; Gao Z; Wang Q
Int J Nanomedicine; 2024; 19():5125-5138. PubMed ID: 38855730
[TBL] [Abstract][Full Text] [Related]
5. Dual depletion of myeloid-derived suppressor cells and tumor cells with self-assembled gemcitabine-celecoxib nano-twin drug for cancer chemoimmunotherapy.
Zhang X; Liang Q; Cao Y; Yang T; An M; Liu Z; Yang J; Liu Y
J Nanobiotechnology; 2024 Jun; 22(1):319. PubMed ID: 38849938
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle drug delivery systems responsive to tumor microenvironment: Promising alternatives in the treatment of triple-negative breast cancer.
Cao Y; Meng F; Cai T; Gao L; Lee J; Solomevich SO; Aharodnikau UE; Guo T; Lan M; Liu F; Li Q; Viktor T; Li D; Cai Y
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(2):e1950. PubMed ID: 38528388
[TBL] [Abstract][Full Text] [Related]
7. A β-Carboline Derivate PAD4 Inhibitor Reshapes Neutrophil Phenotype and Improves the Tumor Immune Microenvironment against Triple-Negative Breast Cancer.
Zhu D; Lu Y; Yan Z; Deng Q; Hu B; Wang Y; Wang W; Wang Y; Wang Y
J Med Chem; 2024 May; 67(10):7973-7994. PubMed ID: 38728549
[TBL] [Abstract][Full Text] [Related]
8. Fn14-Directed DART Nanoparticles Selectively Target Neoplastic Cells in Preclinical Models of Triple-Negative Breast Cancer Brain Metastasis.
Carney CP; Kapur A; Anastasiadis P; Ritzel RM; Chen C; Woodworth GF; Winkles JA; Kim AJ
Mol Pharm; 2023 Jan; 20(1):314-330. PubMed ID: 36374573
[TBL] [Abstract][Full Text] [Related]
9. Innovative Nanomaterials for Targeting Hypoxia to Improve Treatment for Triple-negative Breast Cancer.
Ray SK; Mukherjee S
Recent Pat Biotechnol; 2024; 18(4):269-272. PubMed ID: 37957916
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic modulations in triple-negative breast cancer: Therapeutic implications for tumor microenvironment.
Zhou L; Yu CW
Pharmacol Res; 2024 Jun; 204():107205. PubMed ID: 38719195
[TBL] [Abstract][Full Text] [Related]
11. A multi-mode Rhein-based nano-platform synergizing ferrotherapy/chemotherapy-induced immunotherapy for enhanced tumor therapy.
Zhu X; Xie L; Tian J; Jiang Y; Song E; Song Y
Acta Biomater; 2024 May; 180():383-393. PubMed ID: 38570106
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib Augments Paclitaxel-Induced Immunogenic Cell Death in Triple-Negative Breast Cancer.
Qian X; Yang H; Ye Z; Gao B; Qian Z; Ding Y; Mao Z; Du Y; Wang W
ACS Nano; 2024 Jun; ():. PubMed ID: 38829727
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticle-Mediated Immunotherapy in Triple-Negative Breast Cancer.
Wang R; Huang X; Chen X; Zhang Y
ACS Biomater Sci Eng; 2024 Jun; 10(6):3568-3598. PubMed ID: 38815129
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional Biomimetic Liposomes with Improved Tumor-Targeting for TNBC Treatment by Combination of Chemotherapy, Antiangiogenesis and Immunotherapy.
Lan J; Chen L; Li Z; Liu L; Zeng R; He Y; Shen Y; Zhang T; Ding Y
Adv Healthc Mater; 2024 May; ():e2400046. PubMed ID: 38767575
[TBL] [Abstract][Full Text] [Related]
15. Dual-targeting of tumor cells and subcellular endoplasmic reticulum
Ma K; Diao H; Xu X; Jin Y; Qiu M; Liu Z; Yang C; Zhao J; Chai S; Fang Q; Guo Z; Cui C; Xu J; Yin L; Ma HY
Nanoscale; 2024 May; ():. PubMed ID: 38819371
[TBL] [Abstract][Full Text] [Related]
16. Chondroitin sulfate-based universal nanoparticle delivers angiogenic inhibitor and paclitaxel to exhibit a combination of chemotherapy and anti-angiogenic therapy.
Hou H; Li Y; Tang W; Gao D; Liu Z; Zhao F; Gao X; Ling P; Wang F; Sun F; Tan H
Int J Biol Macromol; 2024 May; 271(Pt 1):132520. PubMed ID: 38772463
[TBL] [Abstract][Full Text] [Related]
17. Dual-targeted nanoparticulate drug delivery systems for enhancing triple-negative breast cancer treatment.
Zheng S; Li M; Xu W; Zhang J; Li G; Xiao H; Liu X; Shi J; Xia F; Tian C; Kamei KI
J Control Release; 2024 Jun; 371():371-385. PubMed ID: 38849089
[TBL] [Abstract][Full Text] [Related]
18. Spleen-targeted delivery systems and strategies for spleen-related diseases.
Huang Z; Sun K; Luo Z; Zhang J; Zhou H; Yin H; Liang Z; You J
J Control Release; 2024 Jun; 370():773-797. PubMed ID: 38734313
[TBL] [Abstract][Full Text] [Related]
19. Combination Nano-Delivery Systems Remodel the Immunosuppressive Tumor Microenvironment for Metastatic Triple-Negative Breast Cancer Therapy.
Bai L; Liu H; You R; Jiang X; Zhang T; Li Y; Shan T; Qian Z; Wang Y; Liu Y; Li C
Mol Pharm; 2024 May; 21(5):2148-2162. PubMed ID: 38536949
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
